Sarafan ChEM-H Seed Grant: Using chemoproteomics to develop new cancer therapeutics
Full program details available on the Sarafan ChEM-H website
Purpose and Scope
The most transformational human health research projects require expertise, techniques, and instrumentation not typically found in academia. To address these needs, Sarafan ChEM-H launched the Nucleus, a cluster of labs led by industry experts in areas like drug development, structural biology, and clinical research who collaborate with Stanford labs.
Sarafan ChEM-H is pleased to announce the expansion of Nucleus capabilities to include chemoproteomics. The Chemoproteomics group provides access to a wide range of mass spectrometry-based methods aimed at studying proteins and their interactions with other proteins or small molecules. This includes: (1) global proteomics (protein abundance profiling, activity-based protein profiling); (2) targeted protein analysis; (3) analysis of post-translational modifications (phosphorylation, acetylation, glycoproteomics); (4) interaction analyses (immunoprecipitation or affinity purification); (5) structural analysis (XL-MS); (6) intact protein analysis.
Through this seed grant, Sarafan ChEM-H is accepting applications from Stanford labs that would like to leverage the Chemoproteomics group at the Nucleus to advance therapeutic approaches in cancer, with a preference for EGFR-mutant lung cancer. Examples of suitable projects include studies focusing on drug target deconvolution, drug effects, biomarker discovery, tissue and plasma profiling, and disease and/or disease cell culture model characterizations.
Successful projects will receive up to $25,000 in the form of in-kind support, which will include consultations with staff, experimental design, instrument time and/or training on the timsTOF HT mass spectrometer, data analysis, and data interpretation. The award period will be 12 months.
Applicants are encouraged to reach out to Dina Schuster, Assistant Director of Chemoproteomics (dschust@stanford.edu) with questions about project applicability or scope, especially if they have no prior chemoproteomics or proteomics experience.
Support Provided
Successful projects will receive $25,000, in the form of in-kind support, which will include consultations with staff, experimental design, instrument time and/or training on the timsTOF HT mass spectrometer, data analysis, and data interpretation. The award period will be 12 months.
Application Instructions
Applications should be submitted directly to Sarafan ChEM-H. You do not need to submit your applications to your Research Process Manager (RPM) in RMG or through your Office of Sponsored Research (OSR) Contract and Grant officer (CGO) for their approval at this time. Selected projects will be required to submit PDRFs via the SERA system to set up University Research Awards.
All application materials must be submitted to Sarafan ChEM-H through the SlideRoom portal.
What is the Nucleus?
The road from molecules to medicines, from discovery to translation, is complex. No single lab is equipped to address each hurdle on the path. The Nucleus at Sarafan ChEM-H is a cluster of labs that bring scientific expertise, tools, and flexibility to Stanford. Led by a unique cadre of industry-trained scientists, the groups at the Nucleus provide industry expertise, cutting-edge instruments and training to Stanford labs. From metabolomics to crystallography, from medicinal chemistry to cell therapies, the Nucleus supercharges research at Stanford.
Learn more at: https://chemh.stanford.edu/research/nucleus
Each project will need to identify a Principal Investigator and a Primary Researcher. The Principal Investigator must be a Stanford faculty with UTL, UML, NTLR or CE appointment. CEs should provide a note from their Chair or Division Chief with their application stating that the Department/Division will cover salary support for time devoted to the project. The Primary Researcher must be a Stanford graduate student or postdoctoral scholar who will devote between 10% and 25% time to the project over a 12-month period.
